Globus Medical reports preliminary 2025 net sales and 2026 outlook

Globus Medical, Inc. reported preliminary unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025.

Rhea-AI Filing Summary

Globus Medical, Inc. reported preliminary unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025. At the same time, the company issued preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026, giving investors an early view of expected performance for the coming year. These updates were shared through a press release dated January 7, 2026, which is furnished as an exhibit to this report.

Insights

Equity research analyst

Globus Medical released preliminary 2025 net sales and early 2026 guidance.

Globus Medical has provided an initial view of its performance by furnishing preliminary unaudited net sales for Q4 and full-year 2025. It also outlined preliminary guidance for certain financial measures for fiscal 2026, which helps frame expectations for the next year.

This type of update is a routine part of the company’s communication cycle and is furnished rather than filed, signaling it is primarily for informational use. The actual impact on valuation depends on how the preliminary figures and 2026 guidance, as detailed in the press release dated January 7, 2026, compare to prior results and market expectations.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Globus Medical (GMED) disclose in this January 7, 2026 report?

Globus Medical disclosed that it issued a press release reporting preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2025, and provided preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026.

Which financial periods are covered by Globus Medical’s preliminary results in this update?

The preliminary unaudited net sales results cover the three-month period and the full fiscal year ended December 31, 2025.

Did Globus Medical (GMED) provide guidance for 2026 in this disclosure?

Yes. The company provided preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026, as described in the press release furnished as Exhibit 99.1.

Where can investors find the detailed numbers for Globus Medical’s preliminary 2025 net sales and 2026 guidance?

The detailed figures are contained in the press release dated January 7, 2026, which is furnished as Exhibit 99.1 and incorporated by reference in this report.

Is the information about Globus Medical’s preliminary results considered filed with the SEC?

No. The company states that the information in this report under Item 2.02, and the related exhibit, is deemed furnished and not filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Who signed this Globus Medical report and in what capacity?

The report was signed on behalf of Globus Medical, Inc. by Kyle Kline, who serves as Chief Financial Officer, Principal Financial Officer, and Senior Vice President.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 04:32 PM Learn about SEC filing dates

0001237831FALSE00012378312026-01-072026-01-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

GLOBUS MEDICAL, INC.

(Exact name of registrant as specified in charter)

DELAWARE

001-35621

04-3744954

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214

(Address of principal executive offices) (Zip Code)

(610) 930-1800

(Registrant’s telephone number, including area code)

Not Applicable

(Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbols			Name of exchange on which registered
Class A Common Stock, par value $.001 per share			GMED			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On January 7, 2026, Globus Medical, Inc. (the “Company”) issued a press release reporting the Company’s preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2025. The press release also included preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibit attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.						Description
99.1						Press Release dated January 7, 2026
104						The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GLOBUS MEDICAL, INC.
						(Registrant)
Dated:			January 7, 2026			/s/ KYLE KLINE
						Kyle Kline
						Chief Financial Officer
						(Principal Financial Officer)
						Senior Vice President